安罗替尼联合紫杉醇和顺铂一线治疗晚期食管鳞癌的疗效分析

目的 探讨安罗替尼联合紫杉醇和顺铂一线治疗晚期食管鳞癌的疗效及不良反应。方法 回顾性分析经病理确诊的晚期食管鳞状细胞癌病例50例，其中24例采用安罗替尼联合紫杉醇和顺铂方案治疗（研究组），26例采用紫杉醇联合顺铂方案治疗（对照组），观察两组疗效和不良反应，并进行随访。结果 研究组和对照组的客观有效率分别为83.33%和53.84%（P<0.05）；疾病控制率分别为100%和96.15%（P>0.05）；中位无进展生存期分别为10.6月和9.13月（P<0.05）；中位生存期分别为13.4月和 11.8月（P<0.05）。研究组常见不良事件为：手足综合征（12.5%）、高血压（12.5%）、鼻出血（8.33%）和蛋白尿（4.16%），较对照组明显增多，但均为Ⅰ~Ⅱ级，均可控制，未影响治疗的连续性。结论 安罗替尼联合紫杉醇和顺铂一线治疗晚期食管鳞癌疗效好，不良反应可耐受。

Clinical Efficacy of Anlotinib Combined with Paclitaxel and Cisplatin as First-lineTreatment of Advanced Esophageal Squamous Cell Carcinoma

Objective To observe the efficacy and side effects of anlotinib combined with paclitaxel and cisplatin as the first-line treatment of advanced esophageal squamous cell carcinoma (ESCC). Methods We retrospectively analyzed 50 cases of advanced esophageal squamous cell carcinoma diagnosed pathologically. Among them, 24 cases were treated with the combination of anlotinib and paclitaxel plus cisplatin (experimental group), and 26 cases were treated with paclitaxel plus cisplatin regimen (control group). The efficacy and adverse reactions were observed and followed up. Results The objective response rates of the experimental and control groups were 83.33% and 53.84% (P<0.05), the disease control rates were 100% and 96.15% (P>0.05), mPFS were 10.6 and 9.13 months (P<0.05), and mOS were 13.4 and 11.8 months (P<0.05). The common adverse events in the experimental group were hand-foot syndrome (12.5%), hypertension (12.5%), epistaxis (8.33%) and proteinuria (4.16%), all of which were grade Ⅰ-Ⅱ and controllable without affecting the continuity of chemotherapy. Conclusion The combination of anlotinib, paclitaxel and cisplatin as the first-line treatment of advanced esophageal squamous cell carcinoma can improve the curative effect and the adverse effects are endurable.